Ignite Creation Date:
2024-05-06 @ 7:59 PM
Last Modification Date:
2024-10-26 @ 3:18 PM
Study NCT ID:
NCT06219174
Status:
RECRUITING
Last Update Posted:
2024-06-28
First Post:
2024-01-12
Brief Title:
Targeting ODC as an Immunotherapeutic Target in STK11 LKB1 Pathway-Deficient NSCLC DFMO
Sponsor:
H Lee Moffitt Cancer Center and Research Institute
Organization:
H Lee Moffitt Cancer Center and Research Institute
Study Overview
Official Title:
Targeting ODC as an Immunotherapeutic Target in STK11 LKB1 Pathway-Deficient NSCLC
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to establish the safety toxicity and tolerability of Difluoromethylornithine DFMO in combination with pembrolizumab in advancedmetastatic Non-Small Cell Lung Cancer NSCLC Researchers also want to investigate how effective DFMO is at treating patients with advanced metastatic NSCLC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None